Duke Immune Profiling Core

The Duke Immune Profiling Core (DIPC) is a Duke Cancer Institute – CCSG designated Shared Resource. The overarching goal of the DIPC is to impact cancer diagnosis and treatment by providing DCI investigators with highest quality human immune profiling data in support of their innovative clinical studies. The DIPC shared resource is comprised of 2 components. The first is a Service component in which DIPC provides comprehensive, highly standardized, state-of-the-art human immunologic profiling services in support of both intra- and extra-mural translational research endeavors, including Phase I/II clinical trials. The second DIPC component focuses on Discovery and utilizes advanced, high-dimensional immunobiologic technologies and resources to stimulate innovative translational research initiatives that will impact existing approaches to cancer diagnosis, prognosis, and treatment. With over 60 years of experience in flow cytometry and immune profiling, we are available to support a wide range of studies from small-scale projects for generating pilot data through clinical trial testing. Additionally, our services include study design, performance of experiments, data collection and analysis, and writing support. Moving forward, we will further enhance our data acquisition and analytical capacity in order to provide DCI members with innovative methods to evaluate patient specimens. The DIPC Shared Resource, which has been in existence since 2019, has provided services to 83 DCI investigators, accounting for 54% of total usage, from all 7 DCI Research Programs during this grant period. During the same period, DIPC provided immune profiling support for 5 cancer immunotherapy clinical trials, and anticipates supporting up to 10 such trials during the next 5-year funding period. Use of this Shared Resource by DCI members contributed to 12 publications over the current project period, 6 of which appeared in high impact journals.